Movement Alert｜GRAIL, Inc. Intraday Rise 5.05% in Regular Trading, FDA review tailwind and UBS target hike supported sentiment

Market Focus10-23

On October 23, GRAIL, Inc. rose 5.05% in Regular Trading, trading at $133.48 per share, with turnover of $21.95 million.

The move aligned with continued positive read-through from Galleri after the FDA advisory committee recommended the test, followed by UBS raising its price target to $175 from $105 while maintaining a Buy rating.

Background details showed the committee voted 10-0 on safety, 6-4 on efficacy, and 7-2 with one abstention on benefit-risk for use in adults aged 50 years or older. Recent analyst commentary indicated the FDA discussion had narrowed toward product positioning and labeling rather than core safety questions, reinforcing expectations for regulatory progress and eventual commercialization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment